The transaction is expected to close in the first half of 2025, subject to the satisfaction of customary closing conditions.

The FDA has accepted for filing and priority review Sentynl Therapeutics’ CUTX-101 NDA for the treatment of Menkes disease.

Under the deal, Candid will have exclusive global rights to a tri-specific TCE discovered by WuXi using its WuXiBody platform. The Chinese company is set to receive an undisclosed upfront payment, as ...

The landscape of pandemic response has been transformed, with new standards being set for clinical excellence. A new report looks at emerging therapies, trial insights, and the innovations shaping the ...

The heart failure market is expected to grow at a 9.6% CAGR from $13.5bn in 2022 to $33.7bn in 2032 in the 7MM.

The China NMPA has approved GSK’s Nucala (mepolizumab) as an add-on treatment along with intranasal corticosteroids to treat CRSwNP.

Orbis Medicines has raised €90m ($94m) in Series A funding to advance the development of its next-generation orally dosable macrocycle drugs.

The US FDA has granted ODD to NMD Pharma’s oral lead development programme, NMD670, designed to treat Charcot-Marie-Tooth disease (CMT).

MRT-6160 is under clinical development by Monte Rosa Therapeutics and currently in Phase I for Rheumatoid Arthritis.

Vebeglogene autotemcel is under clinical development by Lantu Biopharma and currently in Phase II for Beta Thalassaemia.

The decision follows a positive recommendation received from the Committee for Medicinal Products for Human Use (CHMP) in November 2024.

Alphaf-001 is under clinical development by Alpha Fusion and currently in Phase I for Follicular Thyroid Cancer.